Latest Breaking News On - Jamesp howard - Page 1 : comparemela.com

Elixir Medical's Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World's First Site-Specific Antithrombotic Therapeutic Compared to DES

DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months

Elixir Medical Corporation: EuroPCR 2024: Elixir Medical's Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World's First Site-Specific Antithrombotic Therapeutic Compared to DES

Six-Month Clinical Data from DESyne BDS Plus Randomized Controlled Trial (RCT) Presented at TCT 2023 Shines Spotlight on Safety, Effectiveness of World's First Site-Specific Antithrombotic Drug Therapy

Positive six-month clinical data were announced by Elixir Medical during the Transcatheter Cardiovascular Therapeutics (TCT) conference, TCT 2023, in San Francisco, CA today. The DESyne BDS Plus Randomized Controlled Trial (RCT) evaluated DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES).

FDA Approval and First Implant of Orsiro Mission Drug-Eluting Stent System in the U.S.

Ask Dr. Scott: Might the 'nocebo effect' undermine Covid vaccine?

Ask Dr. Scott: Might the ‘nocebo effect’ undermine Covid vaccine? Ask Dr. Scott: Dr. Scott T. Anderson Most of us are familiar with the placebo effect. A pill containing no pharmaceutical agent, often used in a control group when testing a new drug, can lead to subjective improvement in well-being among people taking said product. A similar effect is gaining currency in the medical literature: the “nocebo effect.” In this case, anticipation of side effects leads to adverse subjective feelings in a person taking a medication or even a placebo. Nocebo effects were recently studied with respect to cholesterol-lowering agents, as summarized in Medical News & Perspectives by Anita Slomski. The public perception is that so-called “statin” drugs may cause debilitating muscle pains. A comparative trial, published in the New England Journal of Medicine, demonstrated that 90% of these adverse effects were due to the nocebo effect.